CTOs on the Move

Capstone Development Services,

www.capstonedevservices.com

 
Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Precision Life Sciences

RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...

Levo Therapeutics

Levo Therapeutics is dedicated to advancing science to create more effective Prader-Willi Syndrome Treatments through precision medicine. Come learn more about how and what we are achieving to mitigate and alleviate the symptoms of PWS.

Ambrilia Biopharma

Ambrilia Biopharma Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Orleans Center for Clinical Research

New Orleans Center for Clinical Research is a New Orleans, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.